Back to results

CompletedPhase 3

Efficacy and Safety of Vildagliptin 50mg Bid as an add-on Therapy to Insulin With or Without Metformin, in Patients With Type 2 Diabetes Mellitus

NCT01582230

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Novartis Investigative Site

Beijing, Beijing Municipality, China

+20 additional locations

View on ClinicalTrials.gov

Save this trial

Quick facts

Start date: 2012-04
Enrollment: 293 participants
Sponsor: Novartis Pharmaceuticals
Purpose: treatment

Locations (21)

Novartis Investigative SiteBeijing, Beijing Municipality, China
Novartis Investigative SiteChangsha, Hunan, China
Novartis Investigative SiteChangsha, Hunan, China
Novartis Investigative SiteNanjing, Jiangsu, China
Novartis Investigative SiteWuxi, Jiangsu, China
Novartis Investigative SiteNanchang, Jiangxi, China
Novartis Investigative SiteShenyang, Liaoning, China
Novartis Investigative SiteJinan, Shandong, China
Novartis Investigative SiteXi’an, Shanxi, China
Novartis Investigative SiteChengdu, Sichuan, China
Novartis Investigative SiteBeijing, China
Novartis Investigative SiteShanghai, China
Novartis Investigative SiteTianjin, China
Novartis Investigative SitePasay, Philippines, Philippines
Novartis Investigative SiteMetro Manila, Philippines
Novartis Investigative SiteQuezon City, Philippines
Novartis Investigative SiteSingapore, Singapore, Singapore
Novartis Investigative SiteSingapore, Singapore
Novartis Investigative SiteBangkok, Bangkok, Thailand
Novartis Investigative SiteBangkok, Thailand
Novartis Investigative SiteKhon Kaen, Thailand

Efficacy and Safety of Vildagliptin 50mg Bid as an add-on Therapy to Insulin With or Without Metformin, in Patients With Type 2 Diabetes Mellitus — TrialFind